X0306 4 2018-02-20 0 0001578845 Allergan plc AGN 0001269428 WALSH MATTHEW M CLONSHAUGH BUSINESS AND TECHNOLOGY PARK DUBLIN L2 D17 E400 IRELAND 0 1 0 0 EVP, Chief Financial Officer Ordinary Shares, par value $0.0001 2018-02-20 4 A 0 13076 160.59 A 13076 D Ordinary Shares, par value $0.0001 2018-02-20 4 A 0 9340 160.59 A 22416 D Ordinary Shares, par value $0.0001 2018-02-21 4 P 0 2000 160.94 A 24416 D Performance-Based Restricted Stock Unit 2018-02-20 4 A 0 28021 0 A Ordinary Shares 28021 28021 D The reported securities are restricted share units ("RSUs"), each of which represents a right to receive one ordinary share of Allergan plc. The RSUs were issued pursuant to the provisions of the 2013 Incentive Award Plan of Allergan plc and shall vest 25% on each of February 20, 2019, February 20, 2020, February 20, 2021 and February 20, 2022. Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. The reported securities are RSUs, each of which represents a right to receive one ordinary share of Allergan plc. The RSUs were issued pursuant to the provisions of the 2013 Incentive Award Plan of Allergan plc and shall vest 20% on each of February 20, 2019, February 20, 2020, February 20, 2021, February 20, 2022 and February 20, 2023. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.80 to $160.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Represents performance-based restricted share units ("PSUs") which will vest as to 50% of the total grant on each of December 31, 2020 and December 31, 2021, subject to the achievement by the Issuer of certain performance criteria. Each PSU represents a contingent right to receive a number of ordinary shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. /s/ A. Robert D. Bailey, Attorney-in-Fact for the Reporting Person 2018-02-22